Objectives: Targeting cytokines to sites of disease has clear advantages because it increases their therapeutic index. We designed fusion proteins of the latent associated peptide (LAP) derived from TGF- with various cytokines via a matrix metalloproteinase (MMP) cleavage site. This design confers latency, increased half-life and targeting to sites of inflammation.
Introduction
Most cytokines are produced in an active form, have a very short half-life, have to be administered frequently at high doses, and the widespread expression of their receptors in many tissues contributes to their untargeted pleiotropic effects. However, contrary to most cytokines, transforming growth factor (TGF)- is secreted as a latent, inactive cytokine [1] .
TGF- is produced as a long polypeptide with a precursor protein (LAP or latency associated peptide) at the amino terminal end, which is cleaved intracellularly from TGF- by furin.
Both LAP and TGF- independently dimerise and LAP provides a 'shell-like' structure around TGF- which is non-covalently maintained within this shell [2] . Cys 33 of LAP forms a disulphide bond with the latency TGF--binding protein (LTBP) enabling TGF- deposition in the extracellular matrix [3, 4] .
To overcome the limitations of using most cytokines as therapeutics, we have developed a new method of delivery of cytokines to sites of disease by using the LAP of TGF-. We have made fusion proteins between LAP and several therapeutic agents. We replaced the furin cleavage site in LAP with a collagenous matrix metalloproteinase (MMP) cleavage site and replaced TGF- with IFN- [5] or small anti-inflammatory peptides [6] . Metalloproteinases are tightly regulated enzymes involved in development, cell migration and are highly upregulated by pro-inflammatory cytokines and during tissue remodelling [7] .
We have also mutated Cys 33 to Ser to avoid interactions of our fusion proteins with LTBP, a modification that did not affect secretion levels of LAP fusion proteins [6] .
Previously, we showed that LAP-IFN was latent (inactive), but became active when released by cleavage with recombinant MMP-1 or MMP-3. Release of IFN- biological activity could be detected by incubating LAP-IFN- with synovial fluid from rheumatoid arthritis (RA) and osteoarthritis (OA) patients or by cerebrospinal fluid (CSF) from meningitis and multiple sclerosis (MS) patients but not by the serum, plasma or CSF from non-inflammatory brain diseases [5] . We tested this delivery approach initially in a collageninduced arthritis (CIA) model in DBA/1 mice and showed that plasmid intramuscular injection of LAP-IFN- was more effective at ameliorating established arthritis than nonlatent isoforms containing IFN- at the amino terminal end of LAP (outside the shell) or as an open shell where the LAP was mutated at the double cysteine (to serine) residues 223 and 225 necessary to maintain the 'shell' as a closed structure. Latent IFN- has an extended half-life compared to the free IFN- (37 times longer) or pegylated-IFN- (7 times longer) [5] .
We have also expressed, as LAP fusions, the anti-inflammatory peptides vasoactive intestinal peptide (VIP) and  melanocortin-stimulating hormone (MSH). Both were therapeutic in CIA in DBA/1 mice when delivered by intramuscular DNA delivery after onset of disease compared with the empty LAP construct alone [6] . In addition, LAP- 3 MSH recombinant protein was demonstrated to be more effective in inhibiting urate crystal-induced peritonitis at a 30 fold lower molar concentration than the free  3 MSH peptide. LAP-VIP had a thousand fold longer half-life than free VIP [6] .
Recently, we have also demonstrated that the original specificity of the cleavage site can be changed to that of an aggrecanase cleavage site that is more specific to arthritic disease [8] .
Aggrecanase 1 and 2 (disintegrin-metalloproteinases with thrombospondin motifs; ADAMTS-4 and ADAMTS-5) are regulated by proinflammatory cytokines and are overexpressed in RA and OA. These enzymes cleave aggrecan which is responsible for resisting compressive forces in the joints, followed by essentially irreversible collagen degradation and cartilage destruction [7] .
Using a fully mouse recombinant LAP-agg-IFN- fusion protein we observed slower and more prolonged release with an aggrecanase cleavage site compared to MMP cleavage with synovial fluid of OA patients and improved therapeutic efficacy in CIA. A recombinant protein without a cleavage site was not therapeutic demonstrating the importance of cleavage for efficacy. We also showed by bioluminescence imaging that the delivery is specific to inflamed tissue without effect in other tissues and this was also confirmed by quantitative RT-PCR of IFN-regulated genes and serum IP-10 concentrations (a serum biomarker of IFN activity). As expected, the half-life of these fusion proteins is reduced by a quarter in arthritic animals compared to naïve mice [8] .
The principle of designing a latent cytokine and harnessing the pathological process i.e. the presence of matrix metalloproteinases for drug delivery is an important targeting mechanism, and its applications are broad including autoimmunity, cancer, atherosclerosis and tissue regeneration.
In this manuscript we show that the latent cytokine approach can be applied to a range of other molecules, as latency could be obtained by engineering other cytokines, growth factors and a cytokine antagonist (IL-1ra) that have various molecular configurations. Importantly, this delivery approach, by virtue of its targeting and latency properties, could contribute to the reassessment of therapeutic applications of cytokines that have failed clinical trials due to their unwanted pleiotropism and toxicities.
Materials and Methods

Construction and expression of latent cytokines with human LAP:
The mature (without signal peptide) version of all cytokines and growth factors were cloned by PCR using Pfu-DNA polymerase (Promega, Southampton, UK) in frame between the Nco1 and Xba1 sites of the expression vector TGF-β GS-MMP-GS linker [5] in the plasmid vector pcDNA-3 (Invitrogen, Paisley, UK). Table 1 shows the primers used for each gene. All restriction enzymes were from New England BioLabs (Hitchin, UK). DNA sequences of all constructs were verified by sequencing at the Genome Centre, William Harvey Research Institute. Plasmid DNA was purified from E. coli DH5α using Qiagen maxiprep kits (Crawley, UK) and was transiently transfected into 293T cells using the calcium phosphate co-precipitation method as previously described [9] . For biological assays, 293T cells were incubated in 10% heat inactivated FBS in DMEM (Invitrogen) (with 100U/ml penicillin, 100µg/ml streptomycin and 2mM L-glutamine) and the supernatant collected 48 hours posttransfection. For Western blotting, the secreted proteins were collected in serum-free DMEM.
Construction, expression and purification of mouse LAP-IFN-β fusion recombinant
proteins: These proteins were expressed and purified as previously reported [8] .
Western blotting:
Denaturing SDS-PAGE gels were run at 12% acrylamide with protein molecular weight markers from BioRad (Hemel Hampstead, UK). After electro-transfer onto a Hybond-P:PVDF membrane (GE Healthcare, Little Chalfont, UK). Blocking was carried out using 5 % dried skimmed milk (Marvel) in 0.1 % Tween-20 in PBS (PBST) for 1 hr.
Primary antibody (1:200 to 1:1000) was applied for 1 hour at room temperature in the same blocking solution. Following 3 x 30 mins washes in 50 mls PBST, secondary antibody conjugated to HRP (1:1000) (GE Healthcare) was added for 30 mins. After a further 3 x 15 mins washes, the blots were developed using the enhanced chemiluminescence (ECL) reagents (GE Healthcare) and exposed to autoradiography using Hyperfilm (GE Healthcare).
Films were developed using an AGFA Curix 60 developer (Gevaert, Germany). Primary antibodies used were as follows: anti-mIFN-β rat clone 7F-D3 (1:200) (Santa Cruz, Heidelberg, Germany); anti-mEPO rat IgG2a, clone 148438, at 0.2 µg/ml (R&D Systems);
anti-mIL-4 rat clone BVD4-1D11 at a dilution of 1:100 (Becton Dickinson, Oxford, UK);
anti-mIL-10 clone 500-P60 at a dilution of 1:100 (Peprotech, London, UK); anti-human TGF-β mouse clone TB21 at a dilution of 1:500 (Abcam, Cambridge, UK); anti-human LAP goat polyclonal antibody at a dilution 1:1000 from (R&D Systems); anti-human BMP-7 rabbit polyclonal antibody at 1:2500 (Abcam); Anti-IGF1 1:1000 (R&D Systems). Secondary antibodies used were: rabbit anti-mouse F (ab)2-HRP at 0.5 µg/ml (Zymed, San Francisco, USA); mouse anti-goat-HRP at 1:1000 (Santa Cruz); goat anti-rabbit-HRP at 1:1000 (DAKO, Cambridge UK).
Assessment of latency:
Supernatants from 293T transfected cells were incubated overnight at 37 C with or without recombinant MMP1 (at 30µM) produced in E. coli [10] kindly provided by Prof. H. Nagase, Kennedy Institute of Rheumatology, Imperial College, London).
IL-4 and IL-10 biological activity assays
The activity of mouse IL-4 and IL-10 in the 293T cell supernatants was determined by measuring the proliferation of CT6 lymphocytes [11] or the D-36 mast cells [12] respectively, using the CellTiter-Glo 
IL-1ra-mediated inhibition of IL-1-induced NFB signalling assay
The HeLa 57A cell line that expresses the NF-κB driven firefly luciferase reporter [13] (kindly provided by Prof. R. Hay, University of Dundee, Scotland) was used for this assay.
HeLa 57A cells (1x10 4 )/96 well plate in triplicate were incubated with increasing dilutions of supernatants from LAP-IL-1ra transfected 293T cells (treated or not with MMP1) for 2 hours and then stimulated for 4 hours with recombinant human IL-1β (10 ng/ml) (PeproTech, London, UK). Cells were lysed with reporter lysis buffer (Promega, Southampton, UK) and luminescence recorded using a Microtiter plate luminometer (Dynex Technologies).
TGF-β assay:
Mink lung fibroblast cells expressing the firefly luciferase reporter gene driven by the plasminogen activator-1 promoter as described by Abe et al. [14] (kindly provided by D. Rifkin, New York University, USA) were cultured in DMEM medium supplemented with 10% heat inactivated FBS, 1% penicillin/streptomycin, 1% L-Glutamine and 250g/ml Geneticin (1mg/ml, G-418 sulphate, Invitrogen, Paisley, UK). HCl to 4 volumes supernatant, incubated for 10 minutes at room temperature (to release TGF-β from the LAP) followed by neutralization (1 volume 1.2N NaOH/0.5M HEPES to 5 volumes supernatant).
The mink cells were treated for 14-16 hours, washed once with 1x PBS before the addition of 50l of 1x Passive Lysis Buffer (Promega) and subsequent incubation for 15 minutes at room temperature on a platform rocker. The cells were then placed at -80C for 30 minutes prior to thawing at room temperature for 10 minutes. The freeze/thaw procedure was repeated twice more, followed by titration before transferring 25l of the cell lysate to assembly strips of white microtiter plates (Thermo Electron Corporation, Vantaa, Finland). The luminescence was read using the MLX Microtiter  Plate Luminometer following the addition of 50l of the luciferase assay reagent (Promega).
IL-17 assay:
The activity of LAP-IL-17 in 293T cell supernatants was determined by measuring the secretion of IL-6 from human foetal fibroblasts (HFF2) cells. HFF2 cells were plated in 96-well plates at a density of 10 4 cells/well in 50 l. After the addition of 50 l of supernatant from transfected 293T cells or standards, the plates were incubated at 37  C at 5 % CO 2 for 72 hrs. IL-6 concentration was measured in the HFF2 supernatants by IL-6 duoset ELISA (R&D Systems, Abingdon, UK).
EPO assay:
The human megakaryoblastic cell line UT7 [15] was grown in RPMI and 10% FBS in the presence of GM-CSF (50 ng/ml). Prior to assaying EPO-dependent cell proliferation, cells were put in fresh medium without GM-CSF for 16-24 hrs, then plated in 96 well plates at a density of 2000 cells /well. 293T cell supernatants from LAP-EPO transfected cells, with or without MMP treatment, were also added to separate wells in doubling dilutions. After 72 hrs, cell proliferation was assessed using the CellTiter-Glo assay as described above. A standard curve for EPO was obtained by the addition of doubling dilutions of recombinant EPO (R&D Systems, Abingdon, UK) from 100 ng/ml. Plates were again washed with PBS/Tween and incubated with Streptavidin-HRP complex (GE Healthcare). Plates were again washed and the signal was detected using the TMB microwell substrate system and the reaction stopped by addition of 4M sulphuric acid (100 µl) and absorbance measurements were performed at 450 nm using a Tecan ELISA plate reader as above. The detection limit of this ELISA is 10 -100 pg/ml. 
EAE in Mx2 luc mice: EAE was induced using an EAE induction kit (Hooke
Laboratories, Lawrence, MA, USA) according to the manufacturer's instructions. Animals with a clinical score of 3 were injected with 10 μg of recombinant LAP-agg-IFN-β, LAPmmp-IFN-β or free IFN-β and sacrificed 24 h later. Tissues were dissected from treated mice, snap frozen and stored at -70°C. Serum levels of IP-10 were assessed as previously described [8] .
Luciferase assay:
Luciferase activity in various mouse tissues was determined using the Bright-Glo luciferase assay system (Promega, Southampton, UK). Frozen tissues were added to Glo-lysis buffer (Promega) and homogenized in CK28 Precellys homogenisation tubes (Stretton Scientific, Derbyshire, UK) using a Precellys homogenizer (Stretton Scientific).
Samples were then centrifuged (13,000 rpm for 5 min at 4C) and the lysate collected.
Protein concentrations of tissue lysates were determined using the BCA protein assay (Fisher Scientific) and luciferase activity was determined in 25μl aliquot of the sample containing 5μg of total protein, which was mixed with 25 μl of Bright-Glo luciferase assay substrate (Promega), and light emission measured using a MLX Microtiter ® Plate Luminometer (Dynex Technologies Inc., Chantilly, VA, USA). Values for luciferase activity were expressed as relative light units per microgram of protein.
Quantitation of LAP fusion proteins by competitive ELISA: LAP fusion proteins were
quantified by competition ELISA as described previously [19] using baculo virus expressed recombinant human LAP as competitor (Sigma -Aldrich).
Statistical analysis
Descriptive statistics and significant differences between groups were calculated using MannWhitney U-tests or one-way ANOVA in Graphpad.
Results
Fusion of LAP-MMP to TGF, IL-4, IL-10, IL-17A, BMP-7, EPO, IGF1 and IL-1ra produces latent molecules that upon cleavage with MMP become active
To investigate the applicability of conferring latency to cytokines and growth factors with different structures (dimers such as IL-10, TGF-, IL-17A, BMP-7 or monomers such as IL-4, EPO, and IL-1ra) and different molecular weights we fused their mature sequence to our original LAP-MMP sequence [5] ( fig. 1 ). Transient expression after 293T cell transfection showed that all proteins were expressed efficiently and were cleaved by recombinant MMP-1 ( fig. 2A-H ). In some of these constructs a (GGGGS) 3 linker was used instead of an MMP cleavable site as control. As shown with LAP-EPO this linker is not cleaved by MMP, nor is it active in the bioassay ( fig. 2D and 3F ).
Metalloproteinases are also active during tissue remodelling and differentiation.
Electroporation of plasmids expressing LAP-TGF- and LAP-BMP-7 into chicken limb bud mesenchymal micromass cultures showed that they facilitate chondrogenesis whilst expression of LAP-MMP alone or empty plasmid cannot ( fig. 3H ).
LAP fusion proteins are effective in treatment of EAE.
We have previously shown that plasmid DNA expressing native TGF- delivered intracranially complexed in liposomes is therapeutic in an animal model of MS [18] . Here we assessed whether intraperitoneal injection of syngeneic fibroblasts engineered with a lentiviral vector to express the same amounts of LAP-TGF- or LAP-MMP, 10 days post disease induction affected disease progression. Figure 4 shows that LAP-TGF- but not LAP-MMP expressing fibroblasts can significantly inhibit the development of the acute phase of the disease.
To investigate whether LAP can be used to deliver a therapeutic entity to the brain and spinal cord, we used the reporter mice that express firefly luciferase under the regulation of the IFNinducible MX2 promoter [17] . Measurement of luciferase activity 24 hr after injection of latent IFN-β shows that IFN-β is efficiently released from LAP into the brains of mice with EAE ( fig. 5A ). Interestingly, this release is even more efficient with the aggrecanase cleavage site than with either LAP-MMP-IFN-β or free IFN-β in the spinal cords of EAE mice.
Figure 5B shows that the IFN-β biomarker IP-10 is poorly induced in animals treated with LAP-IFN-β constructs in comparison to free IFN-β.
Discussion
Here we have described the versatility of our latent cytokine technology. We demonstrate that cytokines whose molecular structure differ substantially, for example EPO, IL-4 and IL1ra are monomers; IL-10 and IL-17 are dimers; and TGF- and BMP share similar dimeric folding and cysteine knot structure; could all become latent when cloned after the LAP and the MMP cleavage site. All cytokines could be detected within LAP by their respective antibodies in ELISA and western blotting.
The crystal structure of LAP with TGF- at its centre has recently been elucidated and the strong interactions of TGF- with LAP demonstrated [2] . Crucially, TGF- within the LAP is inaccessible to its receptors (ibid).
Interestingly, BMP-7 is a member of the TGF- family of growth factors that have a LAP that does not provide latency [20] . This may be due in part to the fact that the LAP of BMP-7 lacks the disulfide bonds provided by cysteines in positions 223 and 225 that dimerise LAP from TGF-β. The hydrophobic residues (leucine and isoleucine) in the 1 helix in the LAP of TGF-β interacts strongly with tryptophan 279 and tryptophan 281 of TGF- [2] stabilising the latent structure whilst the opposite face interacts with LTBP [21] . In BMP7, this outward face enables interaction with fibrillin.
We do not envisage that the 'shell' structure provided by LAP is fully closed, particularly with larger cytokines such as IFN- and neither do we expect that LAP will strongly interact with any other cytokine except for its native TGF- and some of its family members. Finally we have also shown that LAP fusion proteins can be used to treat a mouse model of multiple sclerosis and efficiently deliver therapeutics to the brain and spinal cord without systemic side effects. Whether this entry through the blood brain barrier is facilitated by the presence of the RGD sequence in LAP and/or other mechanism(s) requires further investigation.
Conclusions
The data presented here clearly demonstrate the applicability of the latent cytokine technology to a number of therapeutic entities including cytokines of different structures and masses, a cytokine antagonist and growth factors. This broad applicability opens up the possibility that these biologically potent molecules may be harnessed for therapeutic use despite their pleiotropic effects and, in some cases, toxicities. This is an important development as there are many pathological conditions where there is an unmet clinical need for new and more targeted therapies, which may now be possible using this approach. 
